SPPI - Spectrum Pharmaceuticals, Inc.
20.41 0.00 (0.00%)
After hours: 4:53PM EDT
| Previous Close | 20.13 |
| Open | 20.14 |
| Bid | 20.20 x 1200 |
| Ask | 20.50 x 4000 |
| Day's Range | 19.67 - 20.45 |
| 52 Week Range | 9.03 - 25.29 |
| Volume | 954,794 |
| Avg. Volume | 1,462,901 |
| Market Cap | 2.142B |
| Beta | 2.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | Mar 7, 2017 - Mar 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2012-12-18 |
| 1y Target Est | 34.50 |
- Simply Wall St.•5 days ago
Is Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) A Financially Strong Company?
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) with a market-capitalization of US$2.22b, rarely draw their attention. While they are lessRead More...
- Zacks•6 days ago
Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study
Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.
- Business Wire•7 days ago
Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy and Doses First Patient
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has initiated two new cohorts for first-line, locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR or HER2 exon 20 insertion mutations in its current Phase 2 non-small cell lung cancer (NSCLC) clinical trial. Spectrum also announced that it has dosed the first patient in the expanded patient population.
- Market Realist•11 days ago
A Look at Spectrum’s Financial Position in September
In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017. In the first half of the year, Spectrum Pharmaceuticals reported net revenues of $54.7 million compared to $63.4 million in H1 2017.
Market Realist•11 days agoWhy Spectrum Pharmaceuticals Stock Rose ~5% on September 6
On September 6, Spectrum Pharmaceuticals stock closed at $22.25, which is a ~5.70% rise from its close of $21.05 on September 5, 2018. On September 6, Spectrum Pharmaceuticals stock price closed at $22.25, which represents ~146% growth from its 52-week low of $9.03 on September 22, 2017. Spectrum Pharmaceuticals hit its 52-week high of $25.29 on August 27, 2018.
- Zacks•12 days ago
Spectrum Pharmaceuticals (SPPI) Catches Eye: Stock Jumps 5.7%
Spectrum Pharmaceuticals (SPPI) shares rose nearly 6% in the last trading session, amid huge volumes.
- Benzinga•13 days ago
The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Sept. 5) Aptinyx Inc (NASDAQ: APTX ) Avanos Medical Inc (NYSE: AVNS ...
- ACCESSWIRE•13 days ago
Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and NovoCure
NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Major U.S. equities were mixed on Wednesday with tech stocks posting worst daily drop since July dragging Nasdaq lower. The Dow Jones Industrial Average ...
- Business Wire•13 days ago
Spectrum Pharmaceuticals Announces Release of Poziotinib Abstract as Part of the IASLC 19th World Conference on Lung Cancer
HENDERSON, Nev.-- -- The abstract reported new interim data from the EGFR cohort and, for the first time, the HER2 cohort in the MD Anderson Phase 2 trial In the EGFR cohort, an objective response rate of 58% and a disease control rate of 90% were reported In the HER2 cohort, an objective response rate of 50% and a disease control rate of 83% were reported Updated data will be presented in an oral ...
- Benzinga•17 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
The biotech sector notched strong gains last week, capitalizing on the positive overall market sentiment, set in motion by the trade deal between the U.S. and Mexico. Here are a few catalysts that could ...
- Zacks•19 days ago
Implied Volatility Surging for Spectrum Pharmaceuticals (SPPI) Stock Options
Investors in Spectrum Pharmaceuticals (SPPI) need to pay close attention to the stock based on moves in the options market lately.
- GlobeNewswire•19 days ago
Report: Exploring Fundamental Drivers Behind International Bancshares, Morgan Stanley, Equity Residential, Hormel Foods, Spectrum Pharmaceuticals, and Cousins Properties — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of International ...
- Business Wire•20 days ago
Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at two upcoming conferences being held in New York on September 5th and September 6th. The presentations will be webcast live and may be accessed by visiting Spectrum’s website at http://investor.sppirx.com/events-and-presentations. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.
- GlobeNewswire•22 days ago
AVANT DIAGNOSTICS ADDS TWO ESTEEMED, INTERNATIONALLY RECOGNIZED BOARD MEMBERS AND FILES ITS 2016 10-K IN PREPARATION OF GETTING CURRENT WITH THE SEC
Avant Diagnostics, Inc. ("Avant" or the “Company”) (OTC Pink: AVDX), today announced the addition of two internationally known oncology experts, Dr. Rajesh Shrotriya, M.D. and Andy DeLaO, to its Board of Directors, the appointments to be effective on Tuesday, August 28, 2018. Dr. Rajesh Shrotriya, M.D., the former CEO and Chairman of Spectrum Pharmaceuticals (NASDAQ: SPPI), has over four decades of experience in the medical field, first as a dedicated physician and then as a pharmaceutical industry executive.
- Thomson Reuters StreetEvents•25 days ago
Edited Transcript of SPPI earnings conference call or presentation 9-Aug-18 8:30pm GMT
Q2 2018 Spectrum Pharmaceuticals Inc Earnings Call
- Investopedia•last month
Top 4 Small-Cap Stocks for 2018
Looking at growth outlooks and price targets, these four small-cap stocks could be stellar for the rest of 2018.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Alnylam Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 13, 2018 / U.S. equities plunged on Friday as rising currency crisis in Turkey fueled a global market pullback. The Turkish lira is down 20 percent this week, slumping ...
- Motley Fool•last month
Why Spectrum Pharmaceuticals Inc. Is Up Big on Mixed Earnings
Shares jumped even though second-quarter results were mixed. What's going on?
- Zacks•last month
Spectrum (SPPI) Earnings and Sales Miss Estimates in Q2
Spectrum (SPPI) reports wider-than-expected loss in the second quarter and misses on revenues. Rolontis successful in second phase III study.
- Zacks•last month
Spectrum Pharmaceuticals (SPPI) Reports Q2 Loss, Misses Revenue Estimates
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of -16.67% and -13.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Spectrum Pharma: 2Q Earnings Snapshot
On a per-share basis, the Henderson, Nevada-based company said it had profit of 13 cents. Losses, adjusted for one-time gains and costs, came to 21 cents per share. The biotechnology company posted revenue ...
- Business Wire•last month
Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pipeline Update
HENDERSON, Nev.-- -- An oral presentation of updated Phase 2 poziotinib data including EGFR and HER2 patients with exon 20 mutations will occur on September 24 at the World Conference on Lung Cancer in Toronto Spectrum’s current poziotinib Phase 2 study is viewed as the pivotal registrational trial following recent conversations with the FDA Both Phase 3 ROLONTIS ® studies, RECOVER and ADVANCE, ...
- Business Wire•2 months ago
Spectrum Pharmaceuticals Announces Second Quarter 2018 Financial Results Teleconference and Webcast
Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the second quarter 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, August 9, ...
- GlobeNewswire•2 months ago
New Research: Key Drivers of Growth for ICU Medical, A. Schulman, Verso, Eli Lilly, Spectrum Pharmaceuticals, and Intuit — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ICU ...
- ACCESSWIRE•2 months ago
Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / July 23, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
